ECOG randomized patients with advanced NSCLC to 1 of 4 new 3 of the 4 regimens used in ECOG docetaxel/cisplatin, paclitaxel/cisplatin. In the ECOG trial, the only direct comparison of similar regimens, response rates and survival times were similar between patients treated with cisplatin. ECOG was chosen as a plenary session presentation because it is an important trial that reflects the state of care in of metastatic NSCLC—the.

Author: Nikosho Kazrajora
Country: Belgium
Language: English (Spanish)
Genre: Sex
Published (Last): 28 March 2011
Pages: 167
PDF File Size: 4.73 Mb
ePub File Size: 7.99 Mb
ISBN: 236-5-80766-736-8
Downloads: 7837
Price: Free* [*Free Regsitration Required]
Uploader: Aragar

Nonhematologic toxicity was unusual. Lung cancer is the most common cancer in the world and the leading cause of cancer-related deaths in Europe and in other Western countries [ 1 — 3 ]. The study by Rcog et al. Study Design and Results A consortium of centers led by Dr. Disease-free survival was prolonged by 1.

Unfortunately, at the time of diagnosis, the majority of patients already have metastatic disease and a systemic, palliative treatment is the only therapeutic option. Recent randomised trials of platinum-free versus platinum-based combination chemotherapy in advanced NSCLC. A Southwest Oncology Group Trial.

In her commentary on this study, Dr.

However, there is no consistent evidence that combination chemotherapy without platinum is better than third generation drugs given as single agents. ZD, a small-molecule tyrosine-kinase inhibitor targeted against the epidermal growth factor receptor, is one of the most promising new biological agents.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in ecig with advanced non-small-cell lung cancer. Several PS scales are available for clinical use: Toxicity was a major concern in this trial.


Grade 3 or 4 alopecia was more common with PCb.

Lung Cancer Highlights

This decision was made because of a high rate of serious adverse events in patients with PS scores of 2. Email alerts New issue alert. An alternative may be found in the use of irinotecan.

In a meta-analysis evaluating the efficacy of chemotherapy in patients with NSCLC [ 12 dcog, cisplatin-based chemotherapy has shown a slight but statistically significant survival advantage over supportive care. Schiller reported the results of one of the world’s largest randomized trials in metastatic lung cancer comparing four platinum-based doublets.

Elderly patients have peculiar characteristics related to physiological ageing with progressive reduction of organ functions and are at risk of unexpected and unpredictable toxicity. Also, there were differences in treatment delivery between the two trials.

The end points for these large randomized clinical trials were survival, response rate, adverse events, and quality of life QOL. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

It is particularly disappointing that it has been so hard to bring this agent to front-line therapy.


Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review

American College of Chest Physicians. Lower doses of cisplatin could probably fcog better tolerated, but currently there are no data supporting this hypothesis in PS2 patients. Results of ECOG Docetaxel is also commonly used as part of a combined modality regimen in locally or regionally advanced disease, with notable results as consolidation therapy.

A first point of discussion was the evidence supporting the role of chemotherapy itself in PS2 patients. Cremophor EL causes pseudo- non-linear pharmacokinetics of paclitaxel in patients.

Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review

Google Scholar Articles by Rigas, J. Finally, the use of subsequent lines of chemotherapy, which was not scog in the ECOG trial, may have obscured potential differences among the treatments.

The role of non-platinum-based third generation polichemotherapy in PS2 patients. Antiemetic prophylaxis was administered to all patients, and patients receiving cisplatin received hydration. Karnofsky and ECOG performance status 194 in lung cancer: Commentary ECOG was chosen as a plenary session presentation because it is an important trial that reflects the state of care in of metastatic NSCLC—the leading cause of cancer-related death in North America.